The GDF15 targeting agent, ponsegromab, is currently being evaluated in a phase 2 clinical trial of cancer patients with cachexia and elevated GDF15 (NCT05546476) and a separate agent CTL-002 is being tested in combination with ICIs in patients with advanced cancer (NCT04725474). Here, GDF15 is linked to Cachexia.